GLP-1 Therapy Through a Microbiome Lens

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have transformed the management of obesity and type 2 diabetes by improving glycemic control, promoting weight loss, and reducing cardiovascular risk. Traditionally, their effects have been interpreted through a host-centric metabolic framework, largely overlooking the gut microbiome’s role. Emerging evidence positions the microbiome as a systems-level mediator of GLP-1RA efficacy, integrating metabolic, immune, and neuroendocrine outcomes. Preclinical and clinical studies show that GLP-1 RAs remodel gut microbial composition, enriching beneficial taxa such as Akkermansia, Bacteroides, Lactobacillus, and SCFA-producing Roseburia and Faecalibacterium prausnitzii. These shifts enhance intestinal barrier function, reduce systemic inflammation, and stimulate endogenous GLP-1 secretion, establishing feedback loops that amplify therapeutic effects. Individual baseline microbial profiles affect treatment response, while GLP-1RAs also exert direct immunomodulatory and cytoprotective actions in the gut. By linking microbial metabolites to host metabolic and neuroendocrine pathways, this framework highlights the gut microbiome as an active participant rather than a passive responder. Integrating microbiome dynamics into GLP-1RA biology offers a foundation for precision medicine approaches, providing strategies to optimize therapeutic outcomes and broaden clinical benefits beyond glycemic control.

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as a cornerstone in the management of obesity and type 2 diabetes, demonstrating robust efficacy in glycemic control, weight reduction, and cardiovascular risk mitigation [1-3]. Their rapid clinical adoption reflects the growing burden of metabolic disease and the limitations of conventional lifestyle and surgical interventions. Mechanistically, GLP-1 RAs mimic endogenous incretin signaling to regulate satiety, glucose homeostasis, and central appetite pathways, enabling sustained weight loss of approximately 15-25% within the first year of treatment [4-6]. Despite these advances, challenges remain, including gastrointestinal adverse effects, potential lean mass loss, and weight regain following discontinuation [7]. These limitations highlight the need to better define the biological determinants of therapeutic response. Conventional frameworks have largely interpreted GLP-1RA efficacy through a host-centric metabolic lens [8]. In contrast, this review advances a conceptual shift by positioning the gut microbiome as a systems-level mediator that integrates peripheral metabolic regulation with central neuroendocrine outcomes. Emerging evidence indicates that GLP-1 RAs reshape microbial composition and function, while microbiome-derived metabolites reciprocally influence host signaling pathways [9,10]. However, current findings remain predominantly associative, with limited mechanistic resolution. Variability in microbial signatures across studies, compounded by differences in diet, treatment duration, and baseline metabolic status, further limits interpretability [11,12]. Establishing causality between microbiome remodeling and therapeutic outcomes, therefore, remains a central challenge. These gaps underscore the need for a systems-level framework integrating host-microbiome interactions to more precisely define GLP-1-mediated responses.

Gut Microbiome as a Mediator of GLP-1 Therapy

The gut microbiome plays a central role in regulating host metabolism, immune function, and neuroendocrine signaling [13,14]. Increasing evidence suggests that it functions as an active mediator of GLP-1 RA efficacy rather than a passive bystander. GLP-1 RAs promote shifts in microbial composition that enrich beneficial taxa and suppress potentially pathogenic communities [15,16]. These compositional changes are accompanied by functional remodeling, including enhanced intestinal barrier integrity, reduced systemic inflammation, and increased production of short-chain fatty acids. Metabolites such as butyrate and propionate contribute to improved insulin sensitivity, appetite regulation, and modulation of inflammatory responses [17,18]. Notably, microbial metabolites stimulate enteroendocrine L-cells to increase endogenous GLP-1 secretion, establishing a bidirectional feedback loop between host physiology and microbial ecology [19,20]. Collectively, these findings support a model in which therapeutic outcomes arise from an integrated host–microbiome system rather than from isolated pharmacological effects.

Impact of GLP-1 Analogs on Gut Microbiota: Preclinical and Clinical Insights

GLP-1RAs, including liraglutide, semaglutide, and dulaglutide, are increasingly recognized for their capacity to modulate the gut microbiota alongside their established roles in glycemic control and weight reduction [21,22]. Preclinical studies consistently demonstrate that these agents promote microbial configurations enriched in beneficial taxa such as Akkermansia muciniphila, Bacteroides, Lactobacillus, Roseburia, and Faecalibacterium prausnitzii [23,24]. These taxa are prominent producers of short-chain fatty acids (SCFAs), including butyrate and propionate, which contribute to improved insulin sensitivity, enhanced intestinal barrier integrity, and reduced systemic inflammation [25,26]. Mechanistically, GLP-1RAs may influence gut motility, luminal pH, and bile acid metabolism, thereby creating a favorable niche for beneficial microbes and reinforcing the gut–brain-microbiome axis [9,10,27].

Liraglutide, in particular, has been extensively studied in rodent models and demonstrates consistent microbiome remodeling [28,29]. It increases the relative abundance of Akkermansia, Bacteroides, Lactobacillus, Parabacteroides, and Oscillospira. In methionine- and choline-deficient (MCD) diet models, liraglutide restores Bacteroides populations and shifts Erysipelotrichaceae composition from Allobaculum to Turicibacter, suggesting a role in mitigating diet-induced dysbiosis in liver disease contexts [30,31]. In db/db mice, enrichment of SCFA-producing taxa (Parabacteroides, Oscillibacter, Prevotellaceae) is accompanied by a reduction in pro-inflammatory genera (Anaerotruncus, Lachnospiraceae) and improvements in alanine aminotransferase/aspartate aminotransferase (ALT/AST) levels, linking microbial remodeling to both metabolic and hepatic benefits [32,33].

High-resolution taxonomic analyses further indicate that liraglutide stabilizes SCFA-producing communities across major phyla, including Bacteroidota (Bacteroides, Alistipes, Parabacteroides, Butyricimonas) and Bacillota (Lactobacillus, Allobaculum, Clostridium, Oscillospira), while reducing potentially pathogenic taxa such as Staphylococcus, Anaerotruncus, and Flavonifractor [34,35]. Notably, reductions in Prevotella_9 are of particular interest given the association of Prevotella-dominated microbiota with insulin resistance, underscoring the metabolic relevance of GLP-1RA-induced microbial shifts [36,37].

Beyond metabolic regulation, GLP-1 signaling exerts direct anti-inflammatory and cytoprotective effects within the gut. Activation of GLP-1 receptors on intraepithelial lymphocytes (IELs) reduces pro-inflammatory cytokine production, suppresses interferon-stimulated gene (ISG) expression, and limits epithelial cell death [38,39]. In anti-CD3-treated mice, exenatide significantly reduces interferon gamma (IFNG) and ISG expression in intestinal epithelial cells (IECs), along with decreased crypt cell death-effects absent in GLP-1R knockout models-highlighting the critical role of GLP-1R signaling in maintaining intestinal immune homeostasis [40,41]. In colitis models, liraglutide attenuates inflammation, preserves crypt architecture, and limits leukocyte infiltration, further supporting its protective role in intestinal integrity [42,43].

Semaglutide exhibits distinct microbial signatures, including enrichment of Akkermansia, Faecalibaculum, and Allobaculum, alongside improvements in glucose tolerance and gut barrier function [44,45]. Interestingly, some studies report reduced microbial diversity following treatment, suggesting that functional remodeling may be more relevant than diversity metrics in determining therapeutic benefit. 46 In polycystic ovary syndrome (PCOS) models, microbiome alterations are associated with weight loss, while neurobehavioral studies demonstrate reduced hippocampal inflammation and enhanced neurogenesis, supporting a role for GLP-1RAs in modulating the gut-brain axis [47-49].

Clinical findings largely mirror these preclinical observations. Short-term liraglutide treatment induces favorable microbiome shifts, whereas long-term dulaglutide therapy leads to gradual microbial restructuring, paralleling sustained improvements in glycemic control, weight loss, and systemic inflammation [50,51]. Importantly, baseline microbiome composition appears to influence therapeutic outcomes. Higher abundances of Bacteroides dorei and Roseburia inulinivorans are associated with greater reductions in HbA1c, while increased Prevotella copri may attenuate treatment efficacy [52,53]. Across studies, enrichment of key SCFA-producing taxa such as Faecalibacterium prausnitzii and Roseburia consistently correlates with improvements in fasting glucose and lipid profiles [54,55].

Retrospective clinical analyses further suggest that GLP-1RA therapy improves quality of life in patients with inflammatory bowel disease (IBD), particularly those with coexisting type 2 diabetes, highlighting the dual metabolic and immunomodulatory effects of these agents [56,57]. In murine inflammation models, GLP-1RAs promote the expansion of SCFA-producing Firmicutes associated with IL-22 production while suppressing pathogenic taxa such as Staphylococcus, coinciding with reduced epithelial damage and modulation of interferon signaling pathways [58,59]. Table 1 summarizes the effects of GLP-1RAs on gut microbiota, including the types of analogs used, study models, microbial alterations, and ass

Table 1: GLP-1 Analog Effects on Gut Microbiota.

Abbreviations: GLP-1: Glucagon-Like Peptide-1; HFD: High-Fat Diet; T2D: Type 2 Diabetes; MCD: Methionine-Choline Deficient; SCFA: Short-Chain Fatty Acids; ALT: Alanine Aminotransferase; AST: Aspartate Aminotransferase; PCOS: Polycystic Ovary Syndrome; IL-22: Interleukin-22.

Collectively, GLP-1RAs engage a bidirectional regulatory network linking host metabolism, intestinal immunity, and microbial ecology. Microbial-derived SCFAs stimulate endogenous GLP-1 secretion, while GLP-1RAs reshape gut physiology and microbial composition, reinforcing feedback loops that amplify therapeutic effects. These findings support the concept that the gut microbiome is not merely a passive responder but an active biological mediator of GLP-1RA efficacy, providing a strong rationale for microbiome-informed precision therapies in metabolic and inflammatory diseases.

Significance of The Review

This review establishes a systems-level framework that incorporates the gut microbiome into GLP-1 RA biology. It positions the microbiome as an active mediator of therapeutic responses, highlights bidirectional interactions between microbial metabolites and host signaling pathways, and underscores agent-specific microbial signatures. By linking microbiome dynamics to metabolic and neuroendocrine outcomes, this framework broadens the clinical relevance of GLP-1 therapies beyond glycemic control. This integrative perspective provides a conceptual foundation for microbiome-informed precision medicine. 

Limitations and Potential Biases

Despite growing interest, current evidence remains largely associative and does not establish causality. Variability in microbial signatures across studies, coupled with differences in diet, treatment duration, and baseline metabolic status, complicates interpretation and limits reproducibility. Integration of microbiome data with neuroendocrine outcomes remains limited, and longitudinal, multi-omics investigations are scarce. These constraints hinder mechanistic insight and restrict the ability to delineate the temporal dynamics underlying therapeutic responses. The absence of causal human data remains the primary barrier to clinical translation. 

Future Directions

Future research must move beyond associative observations toward longitudinal, multi-omics frameworks capable of capturing dynamic host–microbiome interactions during GLP-1 RA therapy. Identification of predictive microbial and metabolite signatures will be critical to addressing inter-individual variability and enabling microbiome-informed precision medicine. The gut–brain–microbiome axis represents a key integrative pathway through which therapeutic responses may be coordinated. In particular, the extent to which GLP-1 RAs restore central insulin and leptin signaling and how microbial metabolites modulate neuroinflammation and brain function remain to be elucidated. These priorities support the development of integrated therapeutic strategies that combine GLP-1 RAs with microbiome-targeted interventions within a unified systems-level framework.

GLP-1 RAs have redefined the management of obesity and type 2 diabetes by extending their effects beyond glycemic control to encompass immune, neuroendocrine, and microbiome-mediated processes. The gut microbiome emerges as a central mediator of these effects, challenging traditional host-centric models and supporting a systems-level understanding of therapeutic responses. However, current evidence remains largely associative, and mechanistic links to clinical outcomes have yet to be fully established. Addressing these gaps will be critical for translating microbiome insights into more effective and precise therapeutic strategies.

Conflict of Interest

The author does have anything to declare. 

Funding

None.

Generative AI statement

The authors confirm that no content in this manuscript was generated by artificial intelligence (AI) tools without appropriate oversight. Any use of AI-assisted technologies (e.g., for language editing or formatting) has been transparently acknowledged, and the authors have reviewed and verified all content for accuracy, originality, and compliance with ethical standards. The authors take full responsibility for the work, including any errors or inaccuracies.